The constant urge to snack or think about food often diminishes as well
The five most at-risk states: West Virginia Awareness Gap Index: 78.8 (24% GLP-1 usage and 77 searches per 100,000 residents) Kentucky Awareness Gap Index: 76.7 (22% GLP-1 usage and 74 searches per 100,000 residents) Oklahoma Awareness Gap Index: 76.4 (20% GLP-1 usage and 69 searches per 100,000 residents) Alaska Awareness Gap Index: 73.3 (17% GLP-1 usage and 64 searches per 100,000 residents) Alabama Awareness Gap Index: 69.6 (19% GLP-1 usage and 72 searches per 100,000 residents) At the other end of the table, the five safest states benefit primarily from lower prescription rates rather than superior awareness fewer people on the drugs means fewer people exposed to the risk
Morton said those who have a BMI greater than 27 represent about half the country
The evidence base in support of the use of medicines based on glucagon-like peptide 1 beyond glucose control and weight loss was substantially bolstered in 2024, as clinical trial data report benefits of these medicines in people with a range of disorders
[46] Kitano Y, Hashimoto S, Matsumoto H, et al
Phase 2 Clinical Trial Data The landmark Phase 2 trial of retatrutide in obesity was a 48-week, randomized, double-blind, placebo-controlled study published in The New England Journal of Medicine in 2023